Literature DB >> 17922805

Molecular modeling of the prekallikrein structure provides insights into high-molecular-weight kininogen binding and zymogen activation.

E Hooley1, P A McEwan, J Emsley.   

Abstract

BACKGROUND: Prekallikrein (PK) plays a central role in the contact system that activates blood coagulation and is involved in the regulation of blood pressure.
OBJECTIVES: To provide three-dimensional structural data for PK and rationalize the molecular basis of substrate recognition and zymogen activation. PATIENTS/
METHODS: The PK homology model was constructed using the coagulation factor (F) XI crystal structure as a template with the program SWISS-MODEL.
RESULTS: The domain organization of the PK apple domains and serine protease is conserved compared to FXI. Surface charge calculations on the PK model revealed that ligand binding to high-molecular-weight kininogen (HK) is predicted to have two key determinants: a pocket within the apple 2 domain and a basic channel formed at the interface of apple domains 1 and 4. A hereditary mutation resulting in PK deficiency (Gly104Arg) and the Lys140 alpha-kallikrein cleavage site both disrupt HK binding and are shown to map to opposite sides of the apple 2 domain pocket. The model also describes the differences in the apple 4 domain that prevents dimer formation in PK vs. FXI. A C-terminal extension in the PK serine protease domain is described as a potential substrate for prolylcarboxypeptidase.
CONCLUSIONS: The interaction between PK and HK is mediated by two discrete surfaces formed by the PK A1, A2 and A4 domains with charge likely to be a critical component of the binding. A novel mode of PK activation is postulated to involve prolylcarboxypeptidase cleaving at the C-terminus rather than the activation loop.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17922805     DOI: 10.1111/j.1538-7836.2007.02792.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  16 in total

1.  Evidence against a protein in plasma that is a product of a factor XI mRNA splice variant missing exons 6 and 7.

Authors:  David Gailani; Mao-Fu Sun; Qiufang Cheng; Anton Matafonov; Erik I Tucker; Andras Gruber; Jonas Emsley
Journal:  Blood       Date:  2010-08-19       Impact factor: 22.113

2.  A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release.

Authors:  K-A Steen Burrell; J Layzer; B A Sullenger
Journal:  J Thromb Haemost       Date:  2017-08-02       Impact factor: 5.824

Review 3.  Homology modelling: a review about the method on hand of the diabetic antigen GAD 65 structure prediction.

Authors:  Marco Wiltgen; Gernot P Tilz
Journal:  Wien Med Wochenschr       Date:  2009

4.  Allosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants.

Authors:  Rami A Al-Horani; David Gailani; Umesh R Desai
Journal:  Thromb Res       Date:  2015-04-22       Impact factor: 3.944

Review 5.  Structure and function of factor XI.

Authors:  Jonas Emsley; Paul A McEwan; David Gailani
Journal:  Blood       Date:  2010-01-28       Impact factor: 22.113

6.  Highly selective hydrolysis of kinins by recombinant prolylcarboxypeptidase.

Authors:  S M Chajkowski; J Mallela; D E Watson; J Wang; C R McCurdy; J M Rimoldi; Z Shariat-Madar
Journal:  Biochem Biophys Res Commun       Date:  2010-12-16       Impact factor: 3.575

7.  Prolylcarboxypeptidase independently activates plasma prekallikrein (fletcher factor).

Authors:  J Wang; A Matafonov; H Madkhali; F Mahdi; D Watson; A H Schmaier; D Gailani; Z Shariat-Madar
Journal:  Curr Mol Med       Date:  2014       Impact factor: 2.222

Review 8.  Structural and functional features of factor XI.

Authors:  D Gailani; S B Smith
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

Review 9.  Human plasma kallikrein-kinin system: physiological and biochemical parameters.

Authors:  J W Bryant; Z Shariat-Madar
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2009-07

10.  The dimeric structure of factor XI and zymogen activation.

Authors:  Yipeng Geng; Ingrid M Verhamme; Stephen B Smith; Mao-Fu Sun; Anton Matafonov; Qiufang Cheng; Stephanie A Smith; James H Morrissey; David Gailani
Journal:  Blood       Date:  2013-03-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.